BeyondSpring is trading at $0.83, up 5.42%, with no confirmed company-specific catalyst explaining the October 5 move.

  • The September 29 FDA Fast Track and trial-funding news predates the move.
  • BeyondSpring disclosed Nasdaq market-value noncompliance and has until March 29, 2027, to regain compliance; this is background, not a confirmed cause of the rise.
  • Broad-market indices are higher, but available reporting does not establish that broader sentiment caused the move.